Oncology Institute (TOI) director files Form 3 with zero holdings

Rhea-AI Filing Summary

Oncology Institute, Inc. director Mark Stolper has filed an initial insider ownership report showing no holdings in the company’s stock. In this Form 3, he is identified as a director of Oncology Institute, Inc. (ticker TOI) and indicates that he does not beneficially own any non-derivative or derivative securities of the company as of the event date of 01/02/2026. The report is filed as a single-reporting-person filing and is signed by attorney-in-fact Mark Hueppelsheuser under a power of attorney.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

STOLPER MARK

(Last) (First) (Middle)

18000 STUDEBAKER ROAD, SUITE 800

(Street)

CERRITOS CA 90703

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/02/2026

3. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Mark Hueppelsheuser, Attorney-in-fact for Mark Stolper	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does Oncology Institute (TOI) disclose in this Form 3 filing?

This Form 3 shows that director Mark Stolper reports no beneficial ownership of Oncology Institute, Inc. securities, including both non-derivative and derivative instruments, as of the event date.

Who is the reporting person in Oncology Institute (TOI)'s Form 3?

The reporting person is Mark Stolper, who is listed as a director of Oncology Institute, Inc. He is not identified as an officer or a 10% owner in this report.

Does director Mark Stolper own any shares of Oncology Institute (TOI)?

According to this Form 3, no securities are beneficially owned by director Mark Stolper. Both the non-derivative and derivative securities tables are effectively empty, and the remarks section confirms that no securities are beneficially owned.

What is the stated event date in this Oncology Institute (TOI) Form 3?

The Form 3 identifies 01/02/2026 as the Date of Event Requiring Statement, which is the reference date for determining beneficial ownership in this filing.

Are there any insider transactions reported for Oncology Institute (TOI) in this Form 3?

No insider transactions are reported. The Form 3 is an initial statement of beneficial ownership and includes no entries in the transaction tables, consistent with the remark that no securities are beneficially owned.

Who signed the Form 3 for Oncology Institute (TOI)'s director?

The Form 3 is signed by /s/ Mark Hueppelsheuser as attorney-in-fact for Mark Stolper, referencing an Exhibit 24 power of attorney authorizing the signature on behalf of the director.